Head-to-head evidence
Omarigliptin vs SYR-472
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Omarigliptin · Marizev
Developed by Merck & Co.
NCT01682759 · Phase 3 · completed
This trial randomized 751 patients in double-blind fashion to omarigliptin or an active comparator (glimepiride), both added to background metformin, for 54 weeks. The primary endpoint was change in HbA1c (a regulator-accepted, disease-defining measure for diabetes), and the prespecified non-inferiority margin of 0.35% was met: the upper bound of the 95% confidence interval for the treatment difference (0.30%) fell within the margin. The trial was adequately sized, properly blinded, and its primary comparison succeeded as designed, making this strong controlled evidence for omarigliptin, even though omarigliptin showed a numerically smaller HbA1c reduction than glimepiride.
SYR-472
Developed by Takeda Pharmaceutical Company
NCT02324569 · Phase 3 · completed
The 12-week comparison randomized 240 participants and used quadruple blinding with placebo control. The primary HbA1c endpoint was met, with a statistically significant treatment difference, but HbA1c is a surrogate laboratory measure rather than a hard clinical endpoint; the subsequent long-term period was open-label.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Omarigliptin's landscape · SYR-472's landscape